LifeScience Clinical & Diagnostic

Celaid Therapeutics Raises $2.6M to Advance CLD-001 Towards US Clinical Trials

Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 Celaid Therapeutics Inc...

 October 06, 2026 | News

FDA Expands Lilly’s Jaypirca Approval to First-Line CLL/SLL Treatment

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirto...

 October 06, 2026 | News

Genmab’s Rina-S Shows Durable Response in Platinum-Resistant Ovarian Cancer

Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median durat...

 October 06, 2026 | News

Bambusa Doses First Patient in Subcutaneous Cohort of Phase I BBT001 Trial

First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration ...

 October 05, 2026 | News

Rznomics Secures Positive EMA Opinion for Orphan Designation of RZ-001 in Glioma

Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA...

 October 02, 2026 | News

Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of Bispecific ADC TJ102

Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), announced that the first patient h...

 October 02, 2026 | News

Telix Secures FDA Fast Track Designation for BiPASS Prostate Cancer Imaging Programme

FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate ca...

 October 01, 2026 | News

Lilly’s Retatrutide Delivers 20.8% Weight Loss in Phase III Obesity and Type 2 Diabetes Trial

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half...

 October 01, 2026 | News

iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China

 Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...

 September 30, 2026 | News

Innovent Expands Global Phase III IBI363 Trial to Non-Squamous NSCLC

Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization...

 September 29, 2026 | News

Akeso Enrols First Patient in Global Phase III Cadonilimab Trial for Advanced Gastric Cancer

Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...

 September 29, 2026 | News

Oracle Unveils AI-Powered Oncology EHR to Transform Cancer Care

Oracle Health and Life Sciences Summit – Oracle today announced its Oracle Health Oncology EHR. Building on the capabilities of Oracle's modern,...

 September 25, 2026 | News

Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies

- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...

 September 24, 2026 | News

Bio-Techne Opens Düsseldorf Flagship Centre to Accelerate Life Sciences Innovation Across Europe

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and ...

 September 24, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close